默克的斯特romectol（伊维菌素）用于针对轻度COVID-19病例的匈牙利临床试验
在东欧最严重的大流行高峰期间，本月初，
匈牙利国家药房研究所的东欧国家
和欧洲药品管理局
在此处针对轻度COVID-19病例的临床试验中，授权使用默克公司的依维菌素品牌的Stromectol进行临床试验。
这项研究的发起人是Meditop Pharmaceutical Ltd.，
针对这项随机，双盲，安慰剂对照研究的70位参与者
评估伊维菌素在无症状和轻度COVID-19患者中的安全性和有效性。
It is also supported by contract research organization (CRO) Cortex Pharma Services.
Conducted at three (3) trial site locations, the study is planned to commence for a few months and occurs in the middle of the worst pandemic spike this nation has yet experienced.
Hungary’s rate of COVID-19 infection
has doubled since its worst spike in November due to the UK variant of SARS-CoV-2.
Eastern European nations aren’t necessarily as rich as those in the West,
perhaps that’s why already ivermectin has been authorized in
Slovakia,
Macedonia、
Bulgaria.
The Czech Republic
has authorized limited procurement by hospitals for compassionate use.
Will Hungary be next?